Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes

被引：0
|
作者：
Te Li
Xu Wan
Jin Ma
Bin Wu
机构：
[1] Fuwai Yunnan Cardiovascular Hospital,Department of Pharmacy
[2] Affiliated with the Kunming Medical University,Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine
[3] Shanghai Jiaotong University,Department of Endocrinology, Ren Ji Hospital, School of Medicine
[4] Shanghai Jiaotong University,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Cost-effectiveness; Chinese setting; Diabetes; Statin treatment; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2214 / 2223
页数：9
相关论文
共 50 条
  • [41] Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    Nguyen, Hai V.
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 3030 - 3039
  • [42] The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes
    Andrew Lowey
    Sara Moore
    Catherine Norris
    David Wright
    Jonathan Silcock
    Peter Hammond
    Pharmacy World & Science, 2007, 29 : 541 - 545
  • [43] Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
    Tunis, Sandra L.
    Minshall, Michael E.
    Charles, Meaghan St.
    Pandya, Bhavik J.
    Baran, Robert W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3085 - 3096
  • [44] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Vega-Hernandez, Gabriela
    Wojcik, Radek
    Schlueter, Max
    DIABETES THERAPY, 2017, 8 (03) : 513 - 530
  • [45] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez
    Radek Wojcik
    Max Schlueter
    Diabetes Therapy, 2017, 8 : 513 - 530
  • [46] The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes
    Lowey, Andrew
    Moore, Sara
    Norris, Catherine
    Wright, David
    Silcock, Jonathan
    Hammond, Peter
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 541 - 545
  • [47] Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy
    Berto, P
    Munro, V
    Gaddi, A
    Negrini, C
    Hutton, J
    Mast, O
    CLINICAL DRUG INVESTIGATION, 2000, 20 (02) : 109 - 121
  • [48] Cost-Effectiveness Analysis for Statin Therapies in the Primary Prevention of Coronary Heart Disease in Italy
    Patrizia Berto
    Vicky Munro
    Antonio Gaddi
    Cristina Negrini
    John Hutton
    Oliver Mast
    Clinical Drug Investigation, 2000, 20 : 109 - 121
  • [49] Cost-Effectiveness of Implementing a Diabetes Primary Prevention Program in a Military Setting
    Kuo, Shihchen S.
    Bryce, Cindy L.
    Zgibor, Janice C.
    Wolf, Donna L.
    True, Mark W.
    Chen, Hsiang-Yu
    Roberts, Mark S.
    Smith, Kenneth J.
    DIABETES, 2010, 59 : A53 - A53
  • [50] Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: A systematic review
    Rinaldi, Giulia
    Hijazi, Alexa
    Haghparast-Bidgoli, Hassan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
12345